Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

1. Korgavkar K., Xiong M., Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology. 2013;149(11):1295 9. DOI:10.1001/jamadermatol.2013.5526.

2. Zwierzina H., Suciu S., Loeffler-Ragg J., et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19(11):1929 33. DOI:10.1038/sj.leu.2403934.

3. Keehn C.A., Belongie I.P., Shistik G., et al. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14(2):102 11. DOI:10.1177/107327480701400203.

4. Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2 10. DOI:10.12788/j.sder.2018.002.

5. Willemze R. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):11 7. DOI:10.12788/j.sder.2018.004.

6. Olsen E., Vonderheid E., Pimpinelli N., et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) [Internet]. Vol. 110, Blood. Blood; 2007. p. 1713 22. DOI:10.1182/blood-2007-03-055749.

7. Horwitz S.M., Olsen E.A., Duvic M., et al. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach [Internet]. Vol. 6, JNCCN Journal of the National Comprehensive Cancer Network. Jones and Bartlett Publishers; 2008. p. 436 42. DOI:10.6004/jnccn.2008.0033.

8. Delfau-Larue M.-H., Laroche L., Wechsler J., et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000;96(9):2987 92. DOI:10.1182/blood.v96.9.2987.

9. Ponti R., Quaglino P., Novelli M., et al. T-cell receptor γ gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: Correlation with clinical, histological and i. Br J Dermatol. 2005;153(3):565 73. DOI:10.1111/j.1365-2133.2005.06649.x.

10. Kirsch I.R., Watanabe R., O’Malley J.T., et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308). DOI:10.1126/scitranslmed.aaa9122.

11. Matos T.R., de Rie M.A., Teunissen M.B.M. Research Techniques Made Simple: High-Throughput Sequencing of the T-Cell Receptor [Internet]. Vol. 137, Journal of Investigative Dermatology. Elsevier B.V.; 2017. p. e131 8. DOI:10.1016/j.jid.2017.04.001.

12. Scherer F., Kurtz D.M., Diehn M., et al. High-throughput sequencing for noninvasive disease detection in hematologic malignancies [Internet]. Vol. 130, Blood. American Society of Hematology; 2017. p. 440 52. DOI:10.1182/blood-2017-03-735639.

13. Jawed S.I., Myskowski P.L., Horwitz S., et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers [Internet]. Vol. 70, Journal of the American Academy of Dermatology. Mosby Inc.; 2014. p. 205.e1-205.e16. DOI:10.1016/j.jaad.2013.07.049.

14. Rea B., Haun P., Emerson R., et al. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. J Clin Pathol. 2018;71(9):814 20. DOI:10.1136/jclinpath-2018-205004.

15. Ferner R.E. Adverse drug reactions in dermatology [Internet]. Vol. 40, Clinical and Experimental Dermatology. Blackwell Publishing Ltd; 2015. p. 105 10. DOI:10.1111/ced.12572.

16. Federico M., Bellei M., Marcheselli L., et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181(6):760 9. DOI:10.1111/bjh.15258.

17. Huang D.Y., Hu Y.F., Wei N., et al. Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chin Med J (Engl). 2019;132(3):294 301. DOI:10.1097/CM9.0000000000000088.

18. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma [Internet]. Vol. 16, Dermatologic Therapy. Dermatol Ther; 2003. p. 311 21. DOI:10.1111/j.1396-0296.2003.01643.x.

19. Campbell J.M., Bateman E., Stephenson M.D., et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Vol. 78, Cancer Chemotherapy and Pharmacology. Springer Verlag; 2016. p. 27 39. DOI:10.1007/s00280-016-3043-5.

20. Mann B.S., Johnson J.R., Cohen M.H., et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T‐Cell Lymphoma. Oncologist. 2007;12(10):1247 52. DOI:10.1634/theoncologist.12-10-1247.

21. Prince H.M., Kim Y.H., Horwitz S., et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555 66. DOI:10.1016/S0140-6736(17)31266-7.

22. Gerami P., Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31(9):1430 8. DOI:10.1097/PAS.0b013e3180439bdc.

23. Alpdogan O., Kartan S., Johnson W., et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL) [Internet]. Vol. 8, Chinese Clinical Oncology. AME Publishing Company; 2019. DOI:10.21037/cco.2019.01.02.

24. Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016. DOI:10.1182/blood-2016-01-643569.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*